Literature DB >> 25261035

Sigma receptors as potential therapeutic targets for neuroprotection.

Linda Nguyen1, Nidhi Kaushal1, Matthew J Robson1, Rae R Matsumoto2.   

Abstract

Sigma receptors comprise a unique family of proteins that have been implicated in the pathophysiology and treatment of many central nervous system disorders, consistent with their high level of expression in the brain and spinal cord. Mounting evidence indicate that targeting sigma receptors may be particularly beneficial in a number of neurodegenerative conditions including Alzheimer׳s disease, Parkinson׳s disease, stroke, methamphetamine neurotoxicity, Huntington׳s disease, amyotrophic lateral sclerosis, and retinal degeneration. In this perspective, a brief overview is given on sigma receptors, followed by a focus on common mechanisms of neurodegeneration that appear amenable to modulation by sigma receptor ligands to convey neuroprotective effects and/or restorative functions. Within each of the major mechanisms discussed herein, the neuroprotective effects of sigma ligands are summarized, and when known, the specific sigma receptor subtype(s) involved are identified. Together, the literature suggests sigma receptors may provide a novel target for combatting neurodegenerative diseases through both neuronal and glial mechanisms.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Glia; Neurodegeneration; Neurotoxicity; Sigma receptors

Mesh:

Substances:

Year:  2014        PMID: 25261035      PMCID: PMC4454619          DOI: 10.1016/j.ejphar.2014.09.022

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  48 in total

Review 1.  Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function.

Authors:  G Raivich; M Bohatschek; C U Kloss; A Werner; L L Jones; G W Kreutzberg
Journal:  Brain Res Brain Res Rev       Date:  1999-07

Review 2.  Sigma-1 receptor as regulator of neuronal intracellular Ca2+: clinical and therapeutic relevance.

Authors:  François P Monnet
Journal:  Biol Cell       Date:  2005-12       Impact factor: 4.458

3.  SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation.

Authors:  Matthew J Robson; Ryan C Turner; Zachary J Naser; Christopher R McCurdy; James P O'Callaghan; Jason D Huber; Rae R Matsumoto
Journal:  Exp Neurol       Date:  2014-02-06       Impact factor: 5.330

4.  Sigma receptor-mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures.

Authors:  M A DeCoster; K L Klette; E S Knight; F C Tortella
Journal:  Brain Res       Date:  1995-02-06       Impact factor: 3.252

5.  Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia.

Authors:  Christopher Katnik; Waldo R Guerrero; Keith R Pennypacker; Yelenis Herrera; Javier Cuevas
Journal:  J Pharmacol Exp Ther       Date:  2006-09-20       Impact factor: 4.030

6.  Sigma receptor activation reduces infarct size at 24 hours after permanent middle cerebral artery occlusion in rats.

Authors:  Craig T Ajmo; Dionne O L Vernon; Lisa Collier; Keith R Pennypacker; Javier Cuevas
Journal:  Curr Neurovasc Res       Date:  2006-05       Impact factor: 1.990

7.  Protein phosphorylation cascades associated with methamphetamine-induced glial activation.

Authors:  M A Hebert; J P O'Callaghan
Journal:  Ann N Y Acad Sci       Date:  2000-09       Impact factor: 5.691

Review 8.  Interleukin-6 expression and regulation in astrocytes.

Authors:  N J Van Wagoner; E N Benveniste
Journal:  J Neuroimmunol       Date:  1999-12       Impact factor: 3.478

9.  Sigma 1 receptor agonists act as neuroprotective drugs through inhibition of inducible nitric oxide synthase.

Authors:  Kamila Vagnerova; Patricia D Hurn; Anish Bhardwaj; Jeffrey R Kirsch
Journal:  Anesth Analg       Date:  2006-08       Impact factor: 5.108

10.  Sigma-ligands and non-competitive NMDA antagonists inhibit glutamate release during cerebral ischemia.

Authors:  D Lobner; P Lipton
Journal:  Neurosci Lett       Date:  1990-09-04       Impact factor: 3.046

View more
  18 in total

1.  Methamphetamine Induces Dopamine Release in the Nucleus Accumbens Through a Sigma Receptor-Mediated Pathway.

Authors:  David M Hedges; J Daniel Obray; Jordan T Yorgason; Eun Young Jang; Vajira K Weerasekara; Joachim D Uys; Frederick P Bellinger; Scott C Steffensen
Journal:  Neuropsychopharmacology       Date:  2017-11-29       Impact factor: 7.853

2.  Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer's disease.

Authors:  Bitna Yi; James J Sahn; Pooneh Memar Ardestani; Andrew K Evans; Luisa L Scott; Jessica Z Chan; Sangeetha Iyer; Ashley Crisp; Gabriella Zuniga; Jonathan T Pierce; Stephen F Martin; Mehrdad Shamloo
Journal:  J Neurochem       Date:  2017-02       Impact factor: 5.372

3.  Novel Dithiolane-Based Ligands Combining Sigma and NMDA Receptor Interactions as Potential Neuroprotective Agents.

Authors:  Silvia Franchini; Pasquale Linciano; Giulia Puja; Annalisa Tait; Chiara Borsari; Nunzio Denora; Rosa Maria Iacobazzi; Livio Brasili; Claudia Sorbi
Journal:  ACS Med Chem Lett       Date:  2020-04-03       Impact factor: 4.345

4.  Chiral resolution of serial potent and selective σ1 ligands and biological evaluation of (-)-[18F]TZ3108 in rodent and the nonhuman primate brain.

Authors:  Xuyi Yue; Hongjun Jin; Zonghua Luo; Hui Liu; Xiang Zhang; Ethan D McSpadden; Linlin Tian; Hubert P Flores; Joel S Perlmutter; Stanley M Parsons; Zhude Tu
Journal:  Bioorg Med Chem       Date:  2017-01-16       Impact factor: 3.641

5.  Generation of Sigmar1 conditional knockout mouse using CRISPR-Cas9 gene targeting.

Authors:  Liang Huang; Haiyan Xiao; Xiaoling Xie; Fang Hu; Fulei Tang; Sylvia B Smith; Lin Gan
Journal:  Genesis       Date:  2022-05-28       Impact factor: 2.389

Review 6.  Tactics for preclinical validation of receptor-binding radiotracers.

Authors:  Susan Z Lever; Kuo-Hsien Fan; John R Lever
Journal:  Nucl Med Biol       Date:  2016-09-03       Impact factor: 2.408

7.  Methamphetamine increases dopamine release in the nucleus accumbens through calcium-dependent processes.

Authors:  Jordan T Yorgason; David M Hedges; J Daniel Obray; Eun Young Jang; Kyle B Bills; Mark Woodbury; Ben Williams; Mandy J Parsons; Marilou A Andres; Scott C Steffensen
Journal:  Psychopharmacology (Berl)       Date:  2020-01-21       Impact factor: 4.530

8.  Association of sigma-1 receptor with dopamine transporter attenuates the binding of methamphetamine via distinct helix-helix interactions.

Authors:  Liang Xu; Liao Y Chen
Journal:  Chem Biol Drug Des       Date:  2021-04-04       Impact factor: 2.873

9.  (+)-Pentazocine Reduces NMDA-Induced Murine Retinal Ganglion Cell Death Through a σR1-Dependent Mechanism.

Authors:  Jing Zhao; Barbara A Mysona; Azam Qureshi; Lily Kim; Taylor Fields; Graydon B Gonsalvez; Sylvia B Smith; Kathryn E Bollinger
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-02       Impact factor: 4.799

Review 10.  Brain Histamine N-Methyltransferase As a Possible Target of Treatment for Methamphetamine Overdose.

Authors:  Junichi Kitanaka; Nobue Kitanaka; F Scott Hall; George R Uhl; Motohiko Takemura
Journal:  Drug Target Insights       Date:  2016-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.